Sometimes the Run-Of-The-Mill Case of Acne Vulgaris Is More Than It Seems

Total Page:16

File Type:pdf, Size:1020Kb

Sometimes the Run-Of-The-Mill Case of Acne Vulgaris Is More Than It Seems Sometimes the run-of-the-mill case of acne vulgaris is more than it seems. Here’s how to spot and treat common acne foolers. By Julie C. Harper, MD ne of the most common diagnoses made by a conversation about the need to follow the prescribed regimen, dermatologist, acne is easily recognizable by you move in closer for a visual inspection and notice that both physician and patient. In fact, the patient things look different than they did from across the room. The most often has made the diagnosis prior to diagnosis is not acne vulgaris at all. scheduling an appointment. So, a very busy Odermatologist picks up a chart that says, “Chief complaint: Finding the Clues acne vulgaris,” and walks into the exam room. From the door There are several simulators of acne vulgaris that can confound a the doctor can appreciate bumps on the face and maybe even clinician. Though these “imposters” can present with a clinical on the neck and chest. This patient is straightforward! The appearance similar to that of acne, closer inspection often reveals presentation is so clear that a diagnosis is made without close subtle (and sometimes not too subtle) clues that will point to the examination of the skin. Treatment is initiated and the patient true diagnosis. Some deserve special consideration: is scheduled for follow-up in eight weeks. Perioral dermatitis. Perioral dermatitis may certainly be The patient returns for follow-up in eight weeks with mistaken for acne vulgaris. It is seen most commonly in young absolutely no improvement. Of course, compliance is always to middle-aged females, a group that is also susceptible to acne an issue! As you visit with the patient, preparing to ease into a vulgaris. It may be associated with inflammatory acne-like 26 Practical Dermatology August 2006 be seen together. Often the patient presents with an acne con- globata-like appearance. Alternatively, they may have been treated with antibiotics or even isotretinoin with what is con- sidered only a partial response. Some dermatologists might be tempted to prescribe additional courses of isotretion aimed at these resistant acne “cysts.” True epidermoid cysts will not show significant improvement with oral antibiotics or isotretinoin. They are best treated with surgical excision. Rosacea fulminans. Not to be confused with acne fulmi- nans, rosacea fulminans presents in young to middle-aged adult females with a history of minimal acne. Seemingly out- papules that involve the of-the-blue, these individuals go from having clear skin to chin, jawline and nasolabial folds. As the name being disfigured with large inflammatory nodules and pustules. implies, perioral dermatitis is also a dermatitis and therefore is Again the comedo, the hallmark of acne vulgaris, is absent. As associated with redness, dryness and itching. Remember that in acne fulminans, systemic symptoms may be present. the area immediately adjacent to the vermillion border will be Treatment includes systemic steroids alone for weeks to months spared. Acne vulgaris may also affect the perioral skin, particu- followed by a combination of systemic steroids and larly in adult females. What helps to differentiate perioral der- isotretinoin. Once the inflammation appears to be well con- matitis from acne vulgaris is the absence of the comedo. trolled the steroids may be discontinued and isotretinoin con- Unless there is an overlap between perioral dermatitis and tinued appropriately. acne vulgaris, comedones should be absent. Fortunately, treat- Syringomas. Occasionally an appendageal tumor will mask ment is similar for both with tetracycline antibiotics often lead- as acne vulgaris. Eruptive syringomas present around puberty ing to resolution of perioral dermatitis within eight weeks. and may be seen on the face, upper chest and upper back, all However, the typical topical treatments for acne vulgaris areas prone to acne vulgaris. Treating eruptive syringomas is dif- including topical retinoids and benzoyl peroxide may con- ficult. Ablative lasers may offer some cosmetic improvement. tribute to the dryness and irritation associated with perioral Pityrosporum folliculitis. Pityrosporum folliculitis is prob- dermatitis. ably mistaken for acne more often than any of us know. It is Verruca plana. Numerous flat warts can also be mistaken seen most commonly on the trunk in the same distribution as for acne vulgaris. They are small, skin-colored, non-inflamed tinea versicolor. It is characterized by erythematous, follicular papules that may occur anywhere on the body. When they are papules and small pustules and is notoriously itchy. Treatment localized to the face or upper trunk they may mimic come- includes systemic antiyeast medications, including itraconazole donal acne. However, on close inspection, the lesions are not or fluconazole. centered around a follicle and no comedones are visible. Flat Demodex folliculitis. Demodex folliculorum is a mite warts may respond to topical retinoids but may require addi- present in the sebaceous follicles on the face. Whether or not tional treatments, including cryotherapy, imiquimod, and/or Demodex incites inflammation is controversial. However, it is immunotherapy. worth considering Demodex folliculitis in individuals with an Multiple epidermoid cysts. Epidermoid cysts are some- asymmetric, itchy papular eruption on the face. Demodex fol- times confused with nodulocystic acne. The two entities may liculitis has also been reported in patients with HIV. Treatment August 2006 Practical Dermatology 27 Acne Imposters Don’t Be Fooled By Acne Imposters Imposter Clues Treatment Options Perioral dermatitis Area immediately adjacent to the ver- Tetracycline antibiotics; Typical topical million border will be spared; No treatments for acne vulgaris (retinoids comedones visible and benzoyl peroxide) may contribute to dryness and irritation. Verruca plana Lesions not centered around a follicle; Topical retinoids; Additional treat- No comedones visible ments include: cryotherapy, imiquimod, and/or immunotherapy Multiple epidermoid cysts Non-response to oral antibiotics or Surgical excision isotretinoin Rosacea fulminans Absent comdedo; Possible systemic Systemic steroids + oral isotretinoin symptoms; No or minimal history of acne Syringomas Skin-colored papules not centered Ablative lasers around a follicle; no comedones visible Pityrosporum folliculitis Notoriously itchy Systemic antiyeast medications, incl. itraconazole or fluconazole Demodex folliculitis Asymmetric, itchy papular eruption Topical permethrin; Topical or oral on the face metronidazole; Ivermectin orally for resistant cases Gram–negative folliculitis Initial therapeutic response followed Oral isotretinoin by acne flares; Large inflamed crusted papules around nose and mouth Tinea faceii and tinea Annular, erythematous or pustular Antifungals; For deep-seated pustules, barbae eruption systemic therapy likely necessary Sarcoidosis Apple jelly color lesions; Comedones Topical, intralesional or systemic absent; Systemic symptoms in patients steroids, hydroxycholoroquine, with systemic sarcoidosis. minocycline Keratosis pilaris Red, follicular, hyperkeratotic papules Topical retinoids, alpha-hydroxy acids, on the cheeks; Similar changes on the or topical salicylic acid; Low-potency upper extensor arms, buttocks, or topical steroid thighs Rosacea Comedo absent; Papules not always Physician preferred regimen for centered around follicle; rosacea. Telangiectases and facial erythema; History of flushing, triggers (esp. sun- light) Pseudofolliculitis barbae Ingrown hairs evident; Comedones Tetracyclines diminish inflammation; absent Topical retinoids (fordesquamation, to lighten PIH) Eosinophilic folliculitis Often pruritic; May be intermittent, UV therapy; Antipruritics; Systemic alternating periods of flaring and steroids clearing 28 Practical Dermatology August 2006 includes topical permethrin and/or topical or oral metronida- Acne rosacea. Is it acne vulgaris or is it rosacea? Making this zole. Resistant cases may benefit from ivermectin orally. distinction can be more challenging than it initially appears at Gram–negative folliculitis. Gram-negative folliculitis is first blush (no pun intended). Remember that the primary seen in individuals who have known acne vulgaris. These indi- lesion of acne is the comedo. This lesion should be readily viduals have been on numerous antibiotics for relatively long apparent in acne vulgaris and absent in rosacea. Rosacea periods of time. They may have had an initial excellent papules are also not always centered around the follicle and response, but as the lesions become infected with gram nega- telangiectases and facial erythema may be promininent. tive organisms, the acne flares with large inflamed crusted History may also offer some clues to the correct diagnosis. Ask papules around the nose and mouth. Although the name about a tendency to blush easily and ask what effect sunlight would imply that additional antibiotics are required for clear- has on the condition. Sunlight is the most frequently implicat- ing, the treatment of choice is oral isotretinoin. ed exacerbating factor in rosacea. Patients with acne vulgaris Tinea faceii and tinea barbae. Tinea faceii or tinea barbae often report that their acne improves with sunlight exposure. may be very subtle. It may present in any age Pseudofolliculitis barbae. PFB is not acne but group as an annular, erythematous or pustu- Always certainly does look like it. Inflammatory lar eruption. If the patient already has a papules and
Recommended publications
  • Proper Preop Makes for Easier Toenail Surgery
    April 15, 2007 • www.familypracticenews.com Skin Disorders 25 Proper Preop Makes for Easier Toenail Surgery BY JEFF EVANS sia using a digital block or a distal approach to take ef- Senior Writer fect. Premedication with NSAIDs, codeine, or dextro- propoxyphene also may be appropriate, he said. WASHINGTON — Proper early management of in- To cut away the offending section of nail, an English grown toenails may help to decrease the risk of recur- anvil nail splitter is inserted under the nail plate and the rence whether or not surgery is necessary, Dr. C. Ralph cut is made all the way to the proximal nail fold. The hy- Daniel III said at the annual meeting of the American pertrophic, granulated tissue should be cut away as well. Academy of Dermatology. Many ingrown toenails are recurrent, so Dr. Daniel per- “An ingrown nail is primarily acting as a foreign-body forms a chemical matricectomy in nearly all patients after reaction. That rigid spicule penetrates soft surrounding tis- making sure that the surgical field is dry and bloodless. sue” and produces swelling, granulation tissue, and some- The proximal nail fold can be flared back to expose more times a secondary infection, said Dr. Daniel of the de- of the proximal matrix if necessary. Dr. Daniel inserts a Cal- partments of dermatology at the University of Mississippi, giswab coated with 88% phenol or 10% sodium hydroxide Jackson, and the University of Alabama, Birmingham. and applies the chemical for 30 seconds to the portion of For the early management of stage I ingrown toenails the nail matrix that needs to be destroyed.
    [Show full text]
  • Pediatric and Adolescent Dermatology
    Pediatric and adolescent dermatology Management and referral guidelines ICD-10 guide • Acne: L70.0 acne vulgaris; L70.1 acne conglobata; • Molluscum contagiosum: B08.1 L70.4 infantile acne; L70.5 acne excoriae; L70.8 • Nevi (moles): Start with D22 and rest depends other acne; or L70.9 acne unspecified on site • Alopecia areata: L63 alopecia; L63.0 alopecia • Onychomycosis (nail fungus): B35.1 (capitis) totalis; L63.1 alopecia universalis; L63.8 other alopecia areata; or L63.9 alopecia areata • Psoriasis: L40.0 plaque; L40.1 generalized unspecified pustular psoriasis; L40.3 palmoplantar pustulosis; L40.4 guttate; L40.54 psoriatic juvenile • Atopic dermatitis (eczema): L20.82 flexural; arthropathy; L40.8 other psoriasis; or L40.9 L20.83 infantile; L20.89 other atopic dermatitis; or psoriasis unspecified L20.9 atopic dermatitis unspecified • Scabies: B86 • Hemangioma of infancy: D18 hemangioma and lymphangioma any site; D18.0 hemangioma; • Seborrheic dermatitis: L21.0 capitis; L21.1 infantile; D18.00 hemangioma unspecified site; D18.01 L21.8 other seborrheic dermatitis; or L21.9 hemangioma of skin and subcutaneous tissue; seborrheic dermatitis unspecified D18.02 hemangioma of intracranial structures; • Tinea capitis: B35.0 D18.03 hemangioma of intraabdominal structures; or D18.09 hemangioma of other sites • Tinea versicolor: B36.0 • Hyperhidrosis: R61 generalized hyperhidrosis; • Vitiligo: L80 L74.5 focal hyperhidrosis; L74.51 primary focal • Warts: B07.0 verruca plantaris; B07.8 verruca hyperhidrosis, rest depends on site; L74.52 vulgaris (common warts); B07.9 viral wart secondary focal hyperhidrosis unspecified; or A63.0 anogenital warts • Keratosis pilaris: L85.8 other specified epidermal thickening 1 Acne Treatment basics • Tretinoin 0.025% or 0.05% cream • Education: Medications often take weeks to work AND and the patient’s skin may get “worse” (dry and red) • Clindamycin-benzoyl peroxide 1%-5% gel in the before it gets better.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Aars Hot Topics Member Newsletter
    AARS HOT TOPICS MEMBER NEWSLETTER American Acne and Rosacea Society 201 Claremont Avenue • Montclair, NJ 07042 (888) 744-DERM (3376) • [email protected] www.acneandrosacea.org Like Our YouTube Page We encourage you to TABLE OF CONTENTS invite your colleagues and patients to get active in AARS in the Community the American Acne & Don’t forget to attend the 14th Annual AARS Networking Reception tonight! ........... 2 Rosacea Society! Visit Our first round of AARS Patient Videos are being finalized now ............................... 2 www.acneandrosacea.org Save the Date for the 8th Annual AARS Scientific Symposium at SID ..................... 2 to become member and Please use the discount code AARS15 for 15% off of registration to SCALE ........... 2 donate now on www.acneandrosacea.org/ Industry News donate to continue to see Ortho Dermatologics launches first cash-pay prescription program in dermatology . 2 a change in acne and Cutera to unveil excel V+ next generation laser platform at AAD Annual Meeting ... 3 rosacea. TARGET PharmaSolutions launches real-world study .............................................. 3 New Medical Research Epidemiology and dermatological comorbidity of seborrhoeic dermatitis ................... 4 A novel moisturizer with high SPF improves cutaneous barrier function .................... 5 Randomized phase 3 evaluation of trifarotene 50 μG/G cream treatment ................. 5 Open-label, investigator-initiated, single site exploratory trial..................................... 6 Erythematotelangiectatic
    [Show full text]
  • Fucidin H Cream Patient Leaflet
    Scale Get-up Material No Sent by e-maiL l 100% GB 059516-XX Subject Date Date INS 175 x 280 mm 02/04/19 Colour Sign. Sign. Black RBE Preparation Place of production 213 Strength ® Packsize Fucidin H cream Ireland Comments: Page 1 of 2 Pharmacode 213 Font size: Heading: 9 pt, section: 8 pt, linespacing: 3 mm Mock-up for reg. purpose 175 mm IIE007-01 - 175 x 280 mm 175 x 280m Insert 100% PACKAGE LEAFLET: INFORMATION FOR THE USER Fucidin® H cream Fusidic acid and hydrocortisone acetate m Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. 20/01/2004 11/06/2018 IIE007-01 What is in this leaflet: Other medicines and Fucidin H cream 213 1. What Fucidin® H cream is and what it is used for Tell your doctor or pharmacist if you are taking, or have 2. Before you use Fucidin® H cream recently taken or might take any other medicines. 3. How to use Fucidin® H cream 4. Possible side effects Pregnancy and breast-feeding 5.
    [Show full text]
  • Download PDF (Inglês)
    Revista6Vol89ingles_Layout 1 10/10/14 11:08 AM Página 1003 WHAT IS YOUR DIAGNOSIS? 1003 s Case for diagnosis* João Roberto Antonio1 Larissa Cannizza Pacheco de Lucca1 Mariana Perez Borim1 Natália Cristina Pires Rossi1 Guilherme Bueno de Oliveira1 DOI: http://dx.doi.org/10.1590/abd1806-4841.20143156 CASE REPORT A 60-year-old woman reports a 5-year history of violaceous and intensely pruritic lesions on the dorsum and scalp, associated with a 2-year history of hair loss. She also reports decreased hair growth in the axillary and inguinal regions in the same period. Dermatological examination shows small, scaly, erythematous-violaceous, flat papules on the dorsal region; multifocal scarring alopecia areas, with smooth, bright and atrophic surface; discrete hair rarefaction in the axillary and inguinal regions; presence of longitu- FIGURE 2: dinal grooves and some depressions on the surface of Perifollicular the nail plate; no oral lesions (Figures 1 and 2). The erythema with desquamation at histopathology of the dorsal lesion is shown in figure the vertex of the 3A and that of the scalp is shown in figure 3B. scalp; cicatricial The treatment was performed using high- alopecia and potency corticoids and resulted, after three months, in smooth, bright and atrophic surface an improvement of pruritus and a slight lightening of the lesions. A FIGURE 1: B Cutaneous, erythematous- FIGURE 3: A. HE 200x. Interface dermatitis with lichenoid pattern purpuric lesions associated with dermo-epidermic detachment and lymphocytic on the infiltrate in band-like pattern in the upper dermis. B. HE 200x. dorsal region Detail of partially destroyed follicle, with perifollicular fibrosis and perivascular lymphocytic infiltrate Received on 19.09.2013.
    [Show full text]
  • Acute-Onset Alopecia
    PHOTO CHALLENGE Acute-Onset Alopecia Justin P. Bandino, MD; Dirk M. Elston, MD A previously healthy 45-year-old man presented to the dermatology department with abrupt onset of patchy, progressively worsening alopecia of the scalp as well as nausea with emesis and blurry vision of a few weeks’ duration. All symptoms were temporally associated with a new demoli- tion job the patient had started at an industrial site. He reportedcopy 10 other contractors were simi- larly affected. The patient denied paresthesia or other skin changes. On physical examination, large patches of smooth alopecia without ery- thema,not scale, scarring, tenderness, or edema that coalesced to involve the majority of the scalp, eye- brows, and eyelashes (inset) were noted. Do WHAT’S THE DIAGNOSIS? a. alopecia areata b. dioxin-induced alopecia c. phosgene-induced alopecia d. syphilitic alopecia CUTIS e. thallium-induced alopecia PLEASE TURN TO PAGE E25 FOR THE DIAGNOSIS From the Department of Dermatology, Medical University of South Carolina, Charleston. The authors report no conflict of interest. Correspondence: Justin P. Bandino, MD, 171 Ashley Ave, MSC 908, Charleston, SC 29425 ([email protected]). E24 I CUTIS® WWW.MDEDGE.COM/DERMATOLOGY Copyright Cutis 2019. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher. PHOTO CHALLENGE DISCUSSION THE DIAGNOSIS: Thallium-Induced Alopecia t the time of presentation, a punch biopsy speci- pencil point–shaped fractures that shed approximately men of the scalp revealed nonscarring alopecia 1 to 2 months after injury. The 10% of scalp hairs in A with increased catagen hairs; follicular minia- the resting telogen phase have no matrix and thus are turization; peribulbar lymphoid infiltrates; and fibrous unaffected.
    [Show full text]
  • Herb Lotions to Regrow Hair in Patients with Intractable Alopecia Areata Hideo Nakayama*, Ko-Ron Chen Meguro Chen Dermatology Clinic, Tokyo, Japan
    Clinical and Medical Investigations Research Article ISSN: 2398-5763 Herb lotions to regrow hair in patients with intractable alopecia areata Hideo Nakayama*, Ko-Ron Chen Meguro Chen Dermatology Clinic, Tokyo, Japan Abstract The history of herbal medicine in China goes back more than 1,000 years. Many kinds of mixtures of herbs that are effective to diseases or symptoms have been transmitted from the middle ages to today under names such as Traditional Chinese Medicine (TCM) in China and Kampo in Japan. For the treatment of severe and intractable alopecia areata, such as alopecia universalis, totalis, diffusa etc., herb lotions are known to be effective in hair regrowth. Laiso®, Fukisin® in Japan and 101® in China are such effective examples. As to treat such cases, systemic usage of corticosteroid hormones are surely effective, however, considering their side effects, long term usage should be refrained. There are also these who should refrain such as small children, and patients with peptic ulcers, chronic infections and osteoporosis. AL-8 and AL-4 were the prescriptions removing herbs which are not allowed in Japanese Pharmacological regulations from 101, and salvia miltiorrhiza radix (SMR) is the most effective herb for hair growth, also the causation to produce contact sensitization. Therefore, the mechanism of hair growth of these herb lotions in which the rate of effectiveness was in average 64.8% on 54 severe intractable cases of alopecia areata, was very similar to DNCB and SADBE. The most recommended way of developing herb lotion with high ability of hairgrowth is to use SMR but its concentration should not exceed 2%, and when sensitization occurs, the lotion should be changed to Laiso® or Fukisin®, which do not contain SMR.
    [Show full text]
  • Cosmetic Center May Newsletter
    Cosmetic Center May Newsletter DERMATOLOGY ASSOCIATES Keratosis Pilaris May specials “KP” Very common 10 % off Sunscreen skin condition characterized by 10% off Glytone KP Products tiny, hard 20% off Laser Hair Removal bumps. Glytone and Neostrata Peels– Purchase a package of 6 and get 1 Free It can be found on the outer Purchase a Facial and Receive a Free Skin Care Starter Kit arms, thighs, and sometimes Product of the Month Procedure of the Month the buttocks Tilley Hats Facials It is caused by the buildup of Lifetime Warranty Schedule an appointment today for dead skin Waterproof & Float an hour of pampering and (keratin) around relaxation. We will use products Many Different Sizes, Styles, and the hair follicle. suitable for your skin type and Colors to Choose From KP generally condition. gets worse in the SPF 50 winter and often clears in the summer. KP is self-limiting and disappears with age. KP can be treated with products. Mother’s Day is May 10 We have several products in the Relaxing Facials & Gift Certificates make great gifts! Cosmetic Center Mini Facials for the month of May only $45 to treat and help You can also shop ONLINE at Kingsportderm.com and have the items shipped. Melanoma Awareness Month More than 1 million cases of skin cancer are diagnosed in the United States each year, making skin cancer the most common cancer in the United States. ABCDEs of Melanoma Approximately 62,480 cases of melanoma will be A. If you draw a line diagnosed each year, nearly 8,420 cases will lead to deaths.
    [Show full text]
  • A New Insight on Atopic Skin Diathesis: Is It Correlated with the Severity of Melasma
    A New Insight on Atopic Skin Diathesis: Is It Correlated with the Severity of Melasma Danar Wicaksono1*, Rima Mustafa2, Sri Awalia Febriana1, Kristiana Etnawati1 1 Dermatovenereology Department, Faculty of Medicine Universitas Gadjah Mada – Dr. Sardjito General Hospital, Yogyakarta-Indonesia 2 Clinical Epidemiology and Biostatistics Unit, Faculty of Medicine Universitas Gadjah Mada –Dr. Sardjito General Hospital, Yogyakarta-Indonesia Keywords: Melasma, atopic skin diathesis (ASD), MASI score, atopic dermatitis (AD) Abstract: Melasma is a macular lesion of light brown to dark on the sun-exposed area, especially on the face. Atopic Skin Diathesis (ASD) is a clinical term to describe skin atopics with previous, present or future atopic dermatitis (AD). Dennie-Morgan infraorbital folds are secondary creases in the skin below the lower eyelids with a sensitivity of 78% and a specificity of 76% to diagnose AD. Melasma skin is characterized by impaired stratum corneum integrity and a delayed barrier recovery rate. Barrier dysfunction will stimulate keratinocyte to secrete keratinocyte-derived factor, which plays role in skin pigmentation process in melasma. To analyze correlation between ASD and Melasma Area Severity Index (MASI) score in melasma patient. This study is an observational analytic study with cross sectional design. Measurement of ASD and MASI score were done in 60 subjects with melasma who went to dermatology outpatient clinic Dr. Sardjito General Hospital from July 2017 to Januari 2018. The correlation between ASD and MASI score was analyzed using Pearson correlation. The result of this study showed no significant correlation between ASD and MASI scores (r: 0.02, p: 0,85). Crude Relative Risk (RR) for Dennie-Morgan infraorbital folds and MASI score was 4 (1.01-15.87).
    [Show full text]
  • Dovobet Gel Patient Information Leaflet
    L Scale Get-up Material No Sent by e-maiL l Scale Get-up Material No Sent by e-mail 100% Used for: GB 000000-XXComments: Insert, 2 columns Page 1 IIE015-02Subject Daivobet®, Dovobet®, Xamiol ® Date gel. SpaceDate for text: 2 X 67,5 x 580 mm. Subject Date Date INS 160 x 600 mm 05/05/20 Colour Sign. MaterialSign. number must be printed on both sides Colour Sign. Sign. 160 x 600 mm 08/09/2010 JUG Black RBE Material number on page 1, OCRB 8pt kerning+10(Quark)/ Preparation 100% 08/06/2018 OMA Place of productionOCRB MEDIUM 8pt kerning+50(Indesign) Preparation Place of production Strength ® Strength Packsize Dovobet gel Ireland Packsize Ireland Comments: Comments: Page 1 of 2 Font size: 9 pt Mock-up for reg. purpose 160 mm IIE015-02 - 160 x 600 mm - Page 1 of 2 2. 05/05/20 Package leaflet: Information for the user Dovobet® 50 micrograms/g + 0.5 mg/g gel RBE calcipotriol/betamethasone SOP_00867 SOP_003993 and SOP_000647, SOP_000962 Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. 6 • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.
    [Show full text]
  • Acne in Childhood: an Update Wendy Kim, DO; and Anthony J
    FEATURE Acne in Childhood: An Update Wendy Kim, DO; and Anthony J. Mancini, MD cne is the most common chron- ic skin disease affecting chil- A dren and adolescents, with an 85% prevalence rate among those aged 12 to 24 years.1 However, recent data suggest a younger age of onset is com- mon and that teenagers only comprise 36.5% of patients with acne.2,3 This ar- ticle provides an overview of acne, its pathophysiology, and contemporary classification; reviews treatment op- tions; and reviews recently published algorithms for treating acne of differing levels of severity. Acne can be classified based on le- sion type (morphology) and the age All images courtesy of Anthony J. Mancini, MD. group affected.4 The contemporary Figure 1. Comedonal acne. This patient has numerous closed comedones (ie, “whiteheads”). classification of acne based on sev- eral recent reviews is addressed below. Acne lesions (see Table 1, page 419) can be divided into noninflammatory lesions (open and closed comedones, see Figure 1) and inflammatory lesions (papules, pustules, and nodules, see Figure 2). The comedone begins with Wendy Kim, DO, is Assistant Professor of In- ternal Medicine and Pediatrics, Division of Der- matology, Loyola University Medical Center, Chicago. Anthony J. Mancini, MD, is Professor of Pediatrics and Dermatology, Northwestern University Feinberg School of Medicine, Ann and Robert H. Lurie Children’s Hospital of Chi- cago. Address correspondence to: Anthony J. Man- Figure 2. Moderate mixed acne. In this patient, a combination of closed comedones, inflammatory pap- ules, and pustules can be seen. cini, MD, Division of Dermatology Box #107, Ann and Robert H.
    [Show full text]